mv-slider
lazy: true
サブ-ナビゲーション
News
Corporate Guide
Business
Investor Relations
Sustainability
Contact Us
HOME
マルチ3はありません
NEWS
What’s new
Press Release
Investor Relations
Information
2024/02/14
Consolidated finacial results for the nine months ended Dec 31(Under Japanese GAAP)
(368KB)
2023/11/13
Takara Bio Announces "SonuAAV™", a Novel AAV Vector for Efficient Gene Transfer to the Inner Ear Organ.
2023/11/09
Notice Concerning Differences between the Financial Results Forecasts and the Actual Results
(163KB)
2023/11/09
Notice Concerning Revisions to the Financial Results Forecasts
(177KB)
2023/11/09
Consolidated Financial Results for the Six Months Ended September 30, 2023 (Under Japanese GAAP)
(427KB)
Read More
2023/11/13
Takara Bio Announces "SonuAAV™", a Novel AAV Vector for Efficient Gene Transfer to the Inner Ear Organ.
2023/10/12
Construction of the Center for Cell and Gene Processing III, which manufactures mRNA vaccine ingredients and enzymes for mRNA production
2023/10/05
Takara Bio Announces Publication of Results from NY-ESO-1・siTCR™ Gene Therapy Study in Clinical Cancer Research
2023/10/03
Takara Bio Announces Presentation of Comparability Studies for CD19 JAK/STAT CAR-T Cell Technology Transfer
2023/09/25
Takara Bio enters into a license agreement of RetroNectin® with Fondazione Telethon ETS
Read More
2024/02/14
Consolidated finacial results for the nine months ended Dec 31(Under Japanese GAAP)
(368KB)
2023/11/09
Notice Concerning Differences between the Financial Results Forecasts and the Actual Results
(163KB)
2023/11/09
Notice Concerning Revisions to the Financial Results Forecasts
(177KB)
2023/11/09
Consolidated Financial Results for the Six Months Ended September 30, 2023 (Under Japanese GAAP)
(427KB)
2023/08/30
{Delayed] Corporate Governance Report
(1,523KB)
Read More
2023/11/13
Takara Bio Announces "SonuAAV™", a Novel AAV Vector for Efficient Gene Transfer to the Inner Ear Organ.
2023/10/12
Construction of the Center for Cell and Gene Processing III, which manufactures mRNA vaccine ingredients and enzymes for mRNA production
2023/10/05
Takara Bio Announces Publication of Results from NY-ESO-1・siTCR™ Gene Therapy Study in Clinical Cancer Research
2023/10/03
Takara Bio Announces Presentation of Comparability Studies for CD19 JAK/STAT CAR-T Cell Technology Transfer
2023/09/25
Takara Bio enters into a license agreement of RetroNectin® with Fondazione Telethon ETS
Read More
BUSINESS
Read More
Research reagents
Scientific instruments
CDMO
Gene Therapy
INVESTOR
RELATIONS
Read More
SUSTAINABILITY
Read More
COMPANY
Read More
マルチ3はありません
PAGETOP
PAGETOP
CLOSE
MENU
サイト内検索
menu
JA
EN
contact
gnavi-box